C4 Therapeutics recently announces positive results from initial study of CFT7455 in Relapsed/Refractory Multiple Myeloma (R/R MM). CFT7455 is a potent, selective MonoDAC (Monofunctional Degradation Activating Compound) degrader of IKZF1/3 gene. It binds to cereblon (CRBN) E3 ligase with high affinity in Multiple Myeloma and Non-Hodgkin Lymphoma. CFT7455 can act as a single agent or in combination with Dexamethasone for R/R MM patients.